4hon MSN
We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...
Double-digit growth in key products, including Tyvaso, Remodulin, Orenitram, and Unituxin, contributed to the financial success. United Therapeutics Corporation (NASDAQ:UTHR)’s Tyvaso revenue ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a ...
Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.19, expectations were $6.1. Operator: Good morning, and welcome to ...
The increase in Unituxin revenues resulted from an increase in quantities sold and a price increase. Full Year 2024 Compared to Full Year 2023. Total Tyvaso revenues grew by 31 percent to $1,620.4 ...
This is due to competition from generics. Unituxin's sales also increased by 19% to $61 million. The increase was due to both increased demand and higher prices for the drug. The revenue CAGR in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results